<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1210">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03091127</url>
  </required_header>
  <id_info>
    <org_study_id>20150262</org_study_id>
    <nct_id>NCT03091127</nct_id>
  </id_info>
  <brief_title>Real-world Use of Carfilzomib Among Patients With Relapsed MM in Europe</brief_title>
  <official_title>Real-world Evidence of the Use of Carfilzomib Among Patients With Relapsed Multiple Myeloma in Europe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With the recent addition of carfilzomib as a treatment option for multiple myeloma, no data
      is available yet on how the drug is being used outside of the clinical trial setting.

      This study will therefore provide essential data to demonstrate the real world utilization
      of carfilzomib in routine clinical practice, including dosage, administration schedule,
      regimen, duration of treatment and reason for discontinuation in Europe.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the recent addition of carfilzomib as a treatment option for multiple myeloma, no data
      is available yet on how the drug is being used outside of the clinical trial setting.

      The Primary Objective is to describe carfilzomib utilisation in routine clinical practice,
      including dosage, administration schedule, regimen, duration of treatment and reason for
      discontinuation.

      âˆ’ Secondary Objectives:

        -  Describe the population treated with carfilzomib in terms of demographics, multiple
           myeloma (MM) disease characteristics, treatment history, and comorbidities.

        -  Describe the safety profile of carfilzomib in routine clinical practice.

        -  Describe response to treatment as assessed by the physician and recorded in the medical
           file.

        -  Describe healthcare resource utilisation of subjects treated with carfilzomib, in terms
           of unplanned hospitalisations.

        -  Describe the reasons for choosing carfilzomib treatment, dose, and regimen as the MM
           treatment of choice.

        -  Describe specific concomitant therapy (bisphosphonates, thromboprophylaxis,
           antihypertensive treatment, anti-infective treatment) and whether these therapies were
           used as prophylaxis or as treatment.

        -  Describe performance of a cardiovascular assessment at carfilzomib initiation where
           available per routine care (electrocardiogram [ECG], echocardiography, left ventricular
           ejection fraction).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2017</start_date>
  <completion_date type="Anticipated">March 17, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 17, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Carfilzomib starting dose</measure>
    <time_frame>18 months</time_frame>
    <description>Carfilzomib dose at first administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carfilzomib dose</measure>
    <time_frame>18 months</time_frame>
    <description>Carfilzomib dose at subsequent administrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carfilzomib dose modification</measure>
    <time_frame>18 months</time_frame>
    <description>Modification includes change in dose level, dose interruption, and dose delays</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to carfilzomib dose modification</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reason for dose modification</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of cycles started</measure>
    <time_frame>18 months</time_frame>
    <description>Number of carfilzomib treatment cycles started throughout study period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carfilzomib regimen</measure>
    <time_frame>18 months</time_frame>
    <description>Treatment combination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carfilzomib dosing frequency</measure>
    <time_frame>18 months</time_frame>
    <description>Number of administrations per cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carfilzomib dosing schedule</measure>
    <time_frame>18 months</time_frame>
    <description>Timing of carfilzomib administration within treatment cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carfilzomib duration of treatment</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Starting dose of concomitant anti-myeloma agents</measure>
    <time_frame>18 months</time_frame>
    <description>Dose of combination agents (e.g. lenalidomide or dexamethasone) at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose modification for concomitant anti-myeloma agents</measure>
    <time_frame>18 months</time_frame>
    <description>Modification includes change in dose level, dose interruption, and dose delays</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>International Staging System (ISS) score</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eastern Cooperative Oncology Group (ECOG) performance status</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytogenetic risk profile at diagnosis</measure>
    <time_frame>18 months</time_frame>
    <description>Cytogenetic risk profile at diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of CRAB features (i.e. hypercalcemia, renal insufficiency, anemia and/or bone pain)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of comorbidities</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Previously received anti-myeloma treatment</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to prior treatment</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of prior relapses</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to adverse event</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram (ECG) changes</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in left ventricular ejection fraction (LVEF)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initiation or dose increase of antihypertensive treatment</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initiation or dose increase of heart failure treatment</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to carfilzomib treatment</measure>
    <time_frame>18 months</time_frame>
    <description>Physician-assessed response as recorded on the medical charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of relapse</measure>
    <time_frame>18 months</time_frame>
    <description>Molecular, hematologic or symptomatic relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalisations</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant therapy not part of the carfilzomib regimen</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Planned subsequent treatment regimen</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient age</measure>
    <time_frame>18 months</time_frame>
    <description>Patient age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient sex</measure>
    <time_frame>18 months</time_frame>
    <description>Patient sex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient height</measure>
    <time_frame>18 months</time_frame>
    <description>Patient height</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient weight</measure>
    <time_frame>18 months</time_frame>
    <description>Patient weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI (magnetic resonance imaging)</measure>
    <time_frame>18 months</time_frame>
    <description>MRI (magnetic resonance imaging)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PET-CT (positron emission tomography-computed tomography)</measure>
    <time_frame>18 months</time_frame>
    <description>PET-CT (positron emission tomography-computed tomography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum M component</measure>
    <time_frame>18 months</time_frame>
    <description>Serum M component</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine M component</measure>
    <time_frame>18 months</time_frame>
    <description>Urine M component</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum albumin</measure>
    <time_frame>18 months</time_frame>
    <description>Serum albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta-2-microglobulin</measure>
    <time_frame>18 months</time_frame>
    <description>Beta-2-microglobulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of plasma cells in bone marrow</measure>
    <time_frame>18 months</time_frame>
    <description>Percent of plasma cells in bone marrow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate dehydrogenase</measure>
    <time_frame>18 months</time_frame>
    <description>Lactate dehydrogenase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG (electrocardiogram)</measure>
    <time_frame>18 months</time_frame>
    <description>ECG (electrocardiogram)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiogram</measure>
    <time_frame>18 months</time_frame>
    <description>Echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF (left ventricular ejection fraction) assessment</measure>
    <time_frame>18 months</time_frame>
    <description>LVEF (left ventricular ejection fraction) assessment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to response</measure>
    <time_frame>18 months</time_frame>
    <description>Duration in months from the start date of carfilzomib treatment up to 18 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to best response</measure>
    <time_frame>18 months</time_frame>
    <description>Duration in months from the start date of carfilzomib treatment up to 18 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Response status at end of follow-up</measure>
    <time_frame>18 months</time_frame>
    <description>Duration in months from the start date of carfilzomib treatment up to 18 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to progression</measure>
    <time_frame>18 months</time_frame>
    <description>Duration in months from the start date of carfilzomib treatment up to 18 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Frailty score</measure>
    <time_frame>18 months</time_frame>
    <description>Frailty score (fit, intermediate fit or frail) as assessed by physician and recorded on medical charts</description>
  </other_outcome>
  <other_outcome>
    <measure>Enrolment in a patient support program</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Receipt of carfilzomib infusion outside of clinic</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Duration of response to carfilzomib</measure>
    <time_frame>18 months</time_frame>
    <description>Duration in months from the start date of carfilzomib treatment up to 18 months</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Multiple Myeloma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Relapsed Multiple Myeloma
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older at the time of carfilzomib initiation

          -  Experienced a relapse (regardless of the type of relapse; molecular, hematologic,
             and/or symptomatic)

          -  At least one prior line of MM treatment has been received

          -  Carfilzomib treatment has been initiated per routine practice and is currently
             ongoing

          -  At least one administration of carfilzomib in a combination regimen (ie, not
             monotherapy) has been received

          -  Provided written informed consent prior to abstraction of any data Subjects who
             previously received treatment with carfilzomib, either through participation in a
             clinical trial, or through routine practice, are eligible to take part in the study.

        Exclusion Criteria:

        - Subjects who are enrolled in a carfilzomib clinical trial will not be eligible to
        additionally take part in this observational study. If a subject who has enrolled into
        this observational study, also enrolls in a clinical trial in which MM treatment and/or
        disease management is protocol-specified, the subject becomes ineligible and the subject's
        data will be censored from the time the subject enrolled the clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Braunau</city>
        <zip>5280</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rankweil</city>
        <zip>6830</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Schwarzach im Pongau</city>
        <zip>5620</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wiener Neustadt</city>
        <zip>2700</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 21, 2017</lastchanged_date>
  <firstreceived_date>January 30, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
